Top

Published in:

Open Access 01-07-2014 | Original Paper

Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort

Authors: Torsten Pietsch, Rene Schmidt, Marc Remke, Andrey Korshunov, Volker Hovestadt, David T. W. Jones, Jörg Felsberg, Kerstin Kaulich, Tobias Goschzik, Marcel Kool, Paul A. Northcott, Katja von Hoff, André O. von Bueren, Carsten Friedrich, Martin Mynarek, Heyko Skladny, Gudrun Fleischhack, Michael D. Taylor, Friedrich Cremer, Peter Lichter, Andreas Faldum, Guido Reifenberger, Stefan Rutkowski, Stefan M. Pfister

Published in: Acta Neuropathologica | Issue 1/2014

Abstract

This study aimed to prospectively evaluate clinical, histopathological and molecular variables for outcome prediction in medulloblastoma patients. Patients from the HIT2000 cooperative clinical trial were prospectively enrolled based on the availability of sufficient tumor material and complete clinical information. This revealed a cohort of 184 patients (median age 7.6 years), which was randomly split at a 2:1 ratio into a training (n = 127), and a test (n = 57) dataset in order to build and test a risk score for this population. Independent validation was performed in a non-overlapping cohort (n = 83). All samples were subjected to thorough histopathological investigation, CTNNB1 mutation analysis, quantitative PCR, MLPA and FISH analyses for cytogenetic variables, and methylome analysis. By univariable analysis, clinical factors (M-stage), histopathological variables (large cell component, endothelial proliferation, synaptophysin pattern), and molecular features (chromosome 6q status, MYC amplification, subgrouping) were found to be prognostic. Molecular consensus subgrouping (WNT, SHH, Group 3, Group 4) was validated as an independent feature to stratify patients into different risk groups. When comparing methods for the identification of WNT-driven medulloblastoma, this study identified CTNNB1 sequencing and methylation profiling to most reliably identify these patients. After removing patients with particularly favorable (CTNNB1 mutation, extensive nodularity) or unfavorable (MYC amplification) markers, a risk score for the remaining “intermediate molecular risk” population dependent on age, M-stage, pattern of synaptophysin expression, and MYCN copy-number status was identified, with speckled synaptophysin expression indicating worse outcome. Test and independent validation of the score confirmed significant discrimination of patients by risk profile. Methylation subgrouping and CTNNB1 mutation status represent robust tools for the risk stratification of medulloblastoma. A simple clinico-pathological risk score was identified, which was confirmed in a test set and by independent clinical validation.

Available only for authorised users

Cho Y-J, Tsherniak A, Tamayo P et al (2011) Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 29(11):1424–1430. doi:10.1200/jco.2010.28.5148 PubMedCentralPubMedCrossRef

Clifford S, Lusher M, Lindsey J et al (2006) Wnt/wingless pathway activation and chromosome 6 loss characterise a distinct molecular sub-group of medulloblastomas associated with a favourable prognosis. Cell Cycle 5(22):2666–2670PubMedCrossRef

Dahmen RP, Koch A, Denkhaus D et al (2001) Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res 61(19):7039–7043PubMed

Ellison DW, Onilude OE, Lindsey JC et al (2005) β-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children’s Cancer Study Group Brain Tumour Committee. J Clin Oncol 23(31):7951–7957. doi:10.1200/jco.2005.01.5479 PubMedCrossRef

Gajjar A, Chintagumpala M, Ashley D et al (2006) Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7(10):813–820PubMedCrossRef

Garre ML, Cama A, Bagnasco F et al (2009) Medulloblastoma variants: age-dependent occurrence and relation to gorlin syndrome––a new clinical perspective. Clin Cancer Res 15(7):2463–2471. doi:10.1158/1078-0432.ccr-08-2023 PubMedCrossRef

Hoff KV, Hinkes B, Gerber NU et al (2009) Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT[`]91. Eur J Cancer 45(7):1209–1217CrossRef

Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Statist 6(1):65–70

Hovestadt V, Remke M, Kool M et al (2013) Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol 125(6):913–916PubMedCentralPubMedCrossRef

10.

Jakacki RI, Burger PC, Zhou T et al (2012) Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children’s Oncology Group Phase I/II Study. J Clin Oncol 30(21):2648–2653. doi:10.1200/jco.2011.40.2792 PubMedCrossRef

11.

Jones DTW, Jager N, Kool M et al (2012) Dissecting the genomic complexity underlying medulloblastoma. Nature 488(7409):100–105. doi:10.1038/nature11284 PubMedCentralPubMedCrossRef

12.

Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53(282):457–481. doi:10.1080/01621459.1958.10501452 CrossRef

13.

Koch A, Hrychyk A, Hartmann W et al (2007) Mutations of the Wnt antagonist AXIN2(Conductin) result in TCF-dependent transcription in medulloblastomas. Int J Cancer 121(2):284–291PubMedCrossRef

14.

Koch A, Waha A, Tonn J et al (2001) Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 93(3):445–449PubMedCrossRef

15.

Kool M, Jones DTW, Jager N et al (2014) Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 25(3):393–405. doi:10.1016/j.ccr.2014.02.004 PubMedCrossRef

16.

Kool M, Korshunov A, Remke M et al (2012) Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 123(4):465–472PubMedCentralPubMed

17.

Kool M, Koster J, Bunt J et al (2008) Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 3(8):e3088PubMedCentralPubMedCrossRef

18.

Korshunov A, Remke M, Werft W et al (2010) Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol 28(18):3054–3060PubMedCrossRef

19.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of tumours of the central nervous system. IARC Press, Lyon

20.

Northcott P, Jones D, Kool M et al (2012) Medulloblastomics: the end of the beginning. Nat Rev Cancer 12(12):818–834PubMedCentralPubMedCrossRef

21.

Northcott P, Korshunov A, Witt H et al (2010) Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29(11):1408–1414PubMedCrossRef

22.

Packer RJ, Gajjar A, Vezina G et al (2006) Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly Diagnosed average-risk medulloblastoma. J Clin Oncol 24(25):4202–4208. doi:10.1200/jco.2006.06.4980 PubMedCrossRef

23.

Pfaff E, Remke M, Sturm D et al (2010) TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol 28(35):5188–5196. doi:10.1200/JCO.2010.31.1670 PubMedCrossRef

24.

Pfister S, Remke M, Benner A et al (2009) Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 27(10):1627–1636. doi:10.1200/JCO.2008.17.9432 PubMedCrossRef

25.

Rausch T, Jones DT, Zapatka M et al (2012) Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148(1–2):59–71. doi:10.1016/j.cell.2011.12.013 PubMedCentralPubMedCrossRef

26.

Remke M, Hielscher T, Northcott P et al (2011) Adult medulloblastoma is comprised of three major molecular variants. J Clin Oncol 29(19):2717–2723PubMedCrossRef

27.

Rutkowski S, Bode U, Deinlein F et al (2005) Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352(10):978–986. doi:10.1056/NEJMoa042176 PubMedCrossRef

28.

Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30(12):e57. doi:10.1093/nar/gnf056 PubMedCentralPubMedCrossRef

29.

Schwalbe E, Williamson D, Lindsey J et al (2013) DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol 125(3):359–371. doi:10.1007/s00401-012-1077-2 PubMedCrossRef

30.

Taylor MD, Liu L, Raffel C et al (2002) Mutations in SUFU predispose to medulloblastoma. Nat Genet 31(3):306–310PubMedCrossRef

31.

Taylor MD, Northcott P, Korshunov A et al (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123(4):465–472. doi:10.1007/s00401-011-0922-z PubMedCentralPubMedCrossRef

32.

Thompson MC, Fuller C, Hogg TL et al (2006) Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24(12):1924–1931. doi:10.1200/jco.2005.04.4974 PubMedCrossRef

33.

Zhukova N, Ramaswamy V, Remke M et al (2013) Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 31(23):2927–2935. doi:10.1200/jco.2012.48.5052 PubMedCrossRef

Title: Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort
Authors: Torsten Pietsch
Rene Schmidt
Marc Remke
Andrey Korshunov
Volker Hovestadt
David T. W. Jones
Jörg Felsberg
Kerstin Kaulich
Tobias Goschzik
Marcel Kool
Paul A. Northcott
Katja von Hoff
André O. von Bueren
Carsten Friedrich
Martin Mynarek
Heyko Skladny
Gudrun Fleischhack
Michael D. Taylor
Friedrich Cremer
Peter Lichter
Andreas Faldum
Guido Reifenberger
Stefan Rutkowski
Stefan M. Pfister
Publication date: 01-07-2014
Publisher: Springer Berlin Heidelberg
Published in: Acta Neuropathologica / Issue 1/2014
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-014-1276-0

At a glance: The STEP trials

Springer Medicine

Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors

Pathology-based approach to epilepsy surgery

Rapid-onset dystonia-parkinsonism associated with the I758S mutation of the ATP1A3 gene: a neuropathologic and neuroanatomical study of four siblings

Improved health-related quality of life outcomes associated with SHH subgroup medulloblastoma in SIOP-UKCCSG PNET3 trial survivors

Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology

Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts